Gilead Sciences (GILD) News Today $109.95 -0.08 (-0.07%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$109.84 -0.11 (-0.10%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by South Dakota Investment CouncilSouth Dakota Investment Council lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 217,238 shares of the biopharmaceutical company's stock after selling 3,800 shares duringFebruary 23 at 7:21 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension FundFjarde AP Fonden Fourth Swedish National Pension Fund lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 287,363 shares ofFebruary 23 at 7:12 AM | marketbeat.com4,010 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Atlantic Family Wealth LLCAtlantic Family Wealth LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 4,010 shares of the biopharmaceutical company's stock, valued at approximateFebruary 23 at 7:03 AM | marketbeat.comKintegral Advisory LLC Decreases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Kintegral Advisory LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 124,646 shares of the biopharmaceutical company's stocFebruary 23 at 6:50 AM | marketbeat.comPavion Blue Capital LLC Purchases Shares of 2,345 Gilead Sciences, Inc. (NASDAQ:GILD)Pavion Blue Capital LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,345 shares of the biopharmaceutical company's stock, valued at approximatelyFebruary 23 at 6:35 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Howard Capital Management Inc.Howard Capital Management Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,922 shares of the biopharmaceutical coFebruary 23 at 6:18 AM | marketbeat.comBell Bank Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Bell Bank raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 118,187 shares of the biopharmaceutical company's stock after purchasing an additional 5,5February 23 at 6:05 AM | marketbeat.comFisher Funds Management LTD Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Fisher Funds Management LTD bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 66,190 shares of the biopharmaceutical company's stock, valued at approxiFebruary 23 at 5:25 AM | marketbeat.comFirst Horizon Advisors Inc. Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)First Horizon Advisors Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 291,278 shares of the biopharmaceutical compFebruary 23 at 5:25 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Bradley Foster & Sargent Inc. CTBradley Foster & Sargent Inc. CT lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 34,635 shares of the biopharmaceutical company's stockFebruary 23 at 5:20 AM | marketbeat.comTranscend Capital Advisors LLC Has $519,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)Transcend Capital Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,619 shares of the biopharmaceutical company's stock afterFebruary 23 at 4:50 AM | marketbeat.comInsider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD)February 23 at 1:18 AM | gurufocus.comFY2025 EPS Forecast for Gilead Sciences Raised by AnalystGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Gilead Sciences in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopFebruary 22 at 8:48 AM | marketbeat.comGilead Sciences Q4 Earnings TranscriptFebruary 22 at 7:15 AM | marketbeat.comGilead Sciences: 4 Reasons This Stock Has Much More To Rise Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summerFebruary 22 at 7:15 AM | marketbeat.comParadigm Asset Management Co. LLC Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Paradigm Asset Management Co. LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,600 shares of the biopharmaceutical company's sFebruary 22 at 7:06 AM | marketbeat.comING Groep NV Sells 133,302 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)ING Groep NV lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 259,383 shares of the biopharmaceutical companyFebruary 22 at 5:18 AM | marketbeat.comIeq Capital LLC Reduces Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Ieq Capital LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 19.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,660 shares of the biopharmaceutical company's stock afterFebruary 22 at 4:43 AM | marketbeat.comGilead Sciences, Inc. Expands Stake in Arcus Biosciences IncFebruary 22 at 3:56 AM | gurufocus.comBrokers Issue Forecasts for Gilead Sciences FY2025 EarningsFebruary 22 at 2:45 AM | americanbankingnews.comHead to Head Comparison: Gilead Sciences (NASDAQ:GILD) & Vaxcyte (NASDAQ:PCVX)February 22 at 2:13 AM | americanbankingnews.comGilead price target raised to $120 from $105 at BernsteinFebruary 21 at 8:08 PM | markets.businessinsider.comInvestors Buy High Volume of Gilead Sciences Call Options (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) was the target of some unusual options trading activity on Thursday. Investors bought 16,698 call options on the company. This is an increase of approximately 38% compared to the typical volume of 12,087 call options.February 21 at 11:51 AM | marketbeat.comAdvyzon Investment Management LLC Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Advyzon Investment Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 4,523 shares of the biopharmaceutical company's stock, valued at approximately $418,000. A numbeFebruary 21 at 6:17 AM | marketbeat.comHandelsbanken Fonder AB Buys 51,453 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Handelsbanken Fonder AB boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 590,156 shares of the biopharmaceutical company's stFebruary 21 at 6:08 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Good Life Advisors LLCGood Life Advisors LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 58.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,868 shares of the biopharmaceutical company's stock after selling 6,748 shares during the perioFebruary 21 at 4:35 AM | marketbeat.comEli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?February 21 at 4:32 AM | msn.comGilead Sciences Inc (GILD) Announces Participation in Upcoming Investor ConferencesFebruary 20 at 8:30 PM | gurufocus.comGilead’s Seladelpar granted conditional European marketing authorizationFebruary 20 at 6:27 PM | markets.businessinsider.comInsider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells 2,500 Shares of StockGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.February 20 at 5:11 PM | marketbeat.comAssembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trialFebruary 20 at 1:26 PM | msn.comGilead Sciences, Inc. (GILD): Among Stocks That Analysts Think Will Go UpFebruary 20 at 1:26 PM | msn.comGilead Sciences (NASDAQ:GILD) Sets New 1-Year High - Should You Buy?Gilead Sciences (NASDAQ:GILD) Sets New 12-Month High - Time to Buy?February 20 at 11:32 AM | marketbeat.comAlberta Investment Management Corp Sells 151,193 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Alberta Investment Management Corp lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 750,000 shareFebruary 20 at 7:23 AM | marketbeat.comWerba Rubin Papier Wealth Management Sells 6,179 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Werba Rubin Papier Wealth Management lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,916 shares of the biophFebruary 20 at 6:59 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 2,500 Shares of StockFebruary 20 at 5:25 AM | insidertrades.comGilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Atria Wealth Solutions Inc.Atria Wealth Solutions Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,461 shares of the biopharmaceutical coFebruary 20 at 4:20 AM | marketbeat.comGilead Sciences to Present at Upcoming Investor ConferencesFebruary 19, 2025 | businesswire.comDeutsche Bank Aktiengesellschaft Upgrades Gilead Sciences (NASDAQ:GILD) to "Buy"Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $120.00 target price for the company in a research report on Tuesday.February 19, 2025 | marketbeat.comMcdonald Partners LLC Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD)Mcdonald Partners LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,816 shares of the biopharmaceutical company's stock aftFebruary 19, 2025 | marketbeat.comConvergence Investment Partners LLC Has $6.32 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Convergence Investment Partners LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,447 shares of theFebruary 19, 2025 | marketbeat.comNew York State Common Retirement Fund Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)New York State Common Retirement Fund reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,632,088 shares ofFebruary 19, 2025 | marketbeat.comCallahan Advisors LLC Has $604,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Callahan Advisors LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 109.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,540 shares of the biopharmaceutical company's stFebruary 19, 2025 | marketbeat.comTruist Financial Corp Decreases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Truist Financial Corp reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 369,735 shares of the biopharmaceutical company'sFebruary 19, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Principal Financial Group Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,454,658 shares of the biopharmaceutical company's stock after purchaFebruary 19, 2025 | marketbeat.comPrincipal Securities Inc. Purchases 4,468 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Principal Securities Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 45.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,404 shares of the biopharmaceutical company'February 19, 2025 | marketbeat.comBlue Trust Inc. Has $326,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Blue Trust Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 45.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,526 shares of the biopharmaceutical company's stock aFebruary 19, 2025 | marketbeat.comDeutsche Bank Upgrades Gilead Sciences (GILD)February 19, 2025 | msn.comGilead Sciences (NASDAQ:GILD) Rating Increased to Buy at Deutsche Bank AktiengesellschaftFebruary 19, 2025 | americanbankingnews.comGilead Sciences, Inc. (NASDAQ:GILD) Short Interest UpdateGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 22,930,000 shares, a decline of 8.9% from the January 15th total of 25,170,000 shares. Currently, 1.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 7,150,000 shares, the short-interest ratio is currently 3.2 days.February 18, 2025 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼1.240.61▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼6923▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today BMRN News Today NBIX News Today EXEL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GILD Stock Alerts